Abstract
Transmission chains within small urban areas (accommodating∼30% of the European population) greatly contribute to case burden and economic impact during the ongoing COVID-19 pandemic, and should be a focus for preventive measures to achieve containment. Here, at very high spatio-temporal resolution, we analysed determinants of SARS-CoV-2 transmission in a European urban area, Basel-City (Switzerland).
We combined detailed epidemiological, intra-city mobility, and socioeconomic data-sets with whole-genome-sequencing during the first SARS-CoV-2 wave. For this, we succeeded in sequencing 44% of all reported cases from Basel-City and performed phylogenetic clustering and compartmental modelling based on the dominating viral variant (B.1-C15324T; 60% of cases) to identify drivers and patterns of transmission. Based on these results we simulated vaccination scenarios and corresponding healthcare-system burden (intensive-care-unit occupancy).
Transmissions were driven by socioeconomically weaker and highly mobile population groups with mostly cryptic transmissions, whereas amongst more senior population transmission was clustered. Simulated vaccination scenarios assuming 60-90% transmission reduction, and 70-90% reduction of severe cases showed that prioritizing mobile, socioeconomically weaker populations for vaccination would effectively reduce case numbers. However, long-term intensive-care-unit occupation would also be effectively reduced if senior population groups were prioritized, provided there were no changes in testing and prevention strategies.
Reducing SARS-CoV-2 transmission through vaccination strongly depends on the efficacy of the deployed vaccine. A combined strategy of protecting risk groups by extensive testing coupled with vaccination of the drivers of transmission (i.e. highly mobile groups) would be most effective at reducing the spread of SARS-CoV-2 within an urban area. Funding: No dedicated funding was used for this work.
Evidence before this study We searched Google Scholar, PubMed, and medRxiv for articles with the keywords ‘SARS-CoV-2’, ‘transmission’, ‘phylogeny’, ‘city’, and ‘model’ as of February 2021 and evaluated the relevant abstracts and study details where appropriate. The identified studies predominantly evaluated SARS-CoV-2 transmission within large metropolises with only a few studies reporting on European cities, including analyses of London and Geneva. We noted, that studies (even outside Europe) generally differentiated between either phylogenetic analysis or a dynamic modelling approach and did not combine the two, despite the different aspects described. Moreover, the majority of studies evaluate publicly available data for modelling SARS-CoV-2 transmission and to estimate effective reproductive numbers. Such analyses naturally lack a direct relation of cases and relevant socioeconomic, or geographical information on a per case basis. To date, whole-genome-sequencing information has not been used to clearly identify inherently related cases for modelling transmission behaviour in any of the studies assessed. Finally, of the modelling studies reported, none provided a data-driven estimate of vaccine scenarios in a city, for which all model parameters were identified from the same source.
Added value of this study In this comprehensive study we examine SARS-CoV-2 transmission patterns within a medium-sized European city. We benefit from a rich data set allowing us to combine phylogenetic clustering with compartmental modelling based exclusively on sequenced and inherently related cases that are mapped to a residential address, and hence coupled with socioeconomic and demographic information. This allows us to evaluate population groups driving SARS-CoV-2 transmission and to quantify relevant effective reproductive numbers. Moreover, we identify both traceable and cryptic transmission chains allowing us to suggest which measures (such as vaccination vs. effective contact tracing) would be most effective for each group.
Implications of all the available evidence Depending on the specific characteristics of the vaccine, we estimate that vaccination of exclusively the senior population groups will reduce intensive-care-unit occupancy, but overall case number would more effectively be contained by prioritising highly mobile population groups from a socioeconomically weaker background (i.e. transmission drivers), even in the context of comparably shallow socioeconomic gradients within a wealthy European urban area. We identified predominantly clustered transmission amongst more senior or more affluent and less mobile population groups, which implies that extensive testing strategies could be used to more effectively prevent SARS-CoV-2 transmission among these groups. By contrast, mobile, low-income population groups were characterized by cryptic transmission. These are very important findings which could be considered in future vaccine prioritization designs for comparable urban areas.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04351503
Funding Statement
No dedicated funding was used for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the local ethical committee Ethik Kommission Nordwest und Zentralschweiz (EKNZ No. 2020-00769, to be found at https://ongoingprojects. swissethics.ch) and the project was registered at clinicaltrial.gov under NCT04351503.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ These authors share senior authorship
Revised introduction, method section, and discussion with in-depth explanation of choice of study area and method in the main text and supplements.
Data Availability
The SEIR-model code used for this submission will be available on https://github.com/BorgwardtLab/BaselEpi.git. Code that was used for phylogenetic inference and calculation of significance of clusters in specified groups is available at https://github.com/appliedmicrobiologyresearch. SARS-CoV-2 whole genomes from Basel-City are available at gisaid.com and at European Nucleotide Archive (ENA) under accession number PRJEB39887.
